Roth Capital biotech analyst to hold an analyst/industry conference call » 13:2504/0904/09/20
Theravance joining fight against COVID-19 with TD-0903, says Piper Sandler » 12:4604/0904/09/20
Piper Sandler analyst…
Nevro says court upholds patent claims validity in Boston Scientific case » 12:4504/0904/09/20
Nevro (NVRO) announced…
Roth Capital healthcare analysts to hold an analyst/industry conference call » 11:2504/0904/09/20
Analysts discuss Arcturus…
Analysts discuss Arcturus Therapeutics' LUNAR-COV19 vaccine candidate and how STARR technology can induce immunity at low levels of dosed mRNA on an Analyst/Industry conference call to be held on April 9 at 12 pm.
Constellation Pharmaceuticals participates in a conference call with SunTrust » 11:2504/0904/09/20
Bernstein to hold a webinar » 10:5004/0904/09/20
Amgen and Adaptive…
Amgen and Adaptive Biotechnologies participate in a webinar on their strategic collaboration to develop a therapeutic to prevent or treat COVID-19 on April 9 at 11 am hosted by Bernstein. Webcast Link
Fly Intel: Top five analyst initiations » 10:1604/0904/09/20
CUE, GSS, CARR, POST, PRVL
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cue Biopharma (CUE) initiated with a Buy at Stifel. 2. Golden Star Resources (GSS) initiated with a Market Perform at BMO Capital. 3. Carrier Global (CARR) initiated with an Equal Weight at Barclays. 4. Post Holdings (POST) assumed with a Buy at Citi. 5. Prevail Therapeutics (PRVL) initiated with an Overweight at Piper Sandler. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Iovance 'could be name to keep eye on' if Gilead seeks M&A, Dealreporter says » 09:4704/0904/09/20
After Gilead (GILD) gave…
After Gilead (GILD) gave soft guidance for this year, Dealreporter told its readers that if the pharma giant "were to go back to the well in oncology, Iovance Biotherapeutics (IOVA) could be a name to keep an eye on," sources tell The Fly. The biotech company reportedly saw some interest in February and such a hypothetical deal would give Gilead "another shot on goal in cell therapy" to build on its prior acquisition of Kite Pharma, the report added, according to contacts.
Stereotaxis participates in a conference call hosted by Lake Street » 09:2904/0904/09/20
Conference call with…
Sage Therapeutics price target lowered to $65 from $86 at BMO Capital » 09:2704/0904/09/20
BMO Capital analyst Gary…
BMO Capital analyst Gary Nachman lowered the firm's price target on Sage Therapeutics to $65 from $86 but keeps an Outperform rating on the shares. The analyst says the company's corporate restructuring announcement to free up $170M in cost savings is not surprising given the uncertain COVID-19 environment, adding that he agrees with the decision to prioritize resources to higher-value opportunities in the pipeline. Nachman also cuts his FY20 and FY21 EPS views on Sage to ($8.25) from ($9.39) and to ($5.67) from ($7.25).